{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:51:18Z","timestamp":1792000278047,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.urology.2016.07.030","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T20:55:31Z","timestamp":1472158531000},"page":"16-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"special_numbering":"C","title":["Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis"],"prefix":"10.1016","volume":"100","author":[{"given":"Ethan L.","family":"Matz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2016.07.030_bib0010","author":"FDA"},{"key":"10.1016\/j.urology.2016.07.030_bib0015","author":"NIH National Cancer Institute"},{"key":"10.1016\/j.urology.2016.07.030_bib0020","author":"FDA"},{"key":"10.1016\/j.urology.2016.07.030_bib0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s005200050149","article-title":"Use of mesna to prevent ifosfamide-induced urotoxicity","volume":"6","author":"Siu","year":"1998","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.urology.2016.07.030_bib0030","series-title":"Cancer Facts and Figures","author":"American Cancer Society","year":"2016"},{"issue":"suppl 2","key":"10.1016\/j.urology.2016.07.030_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000073351","article-title":"Side effects of ifosfamide","volume":"65","author":"Klastersky","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.urology.2016.07.030_bib0040","doi-asserted-by":"crossref","DOI":"10.1007\/BF00638623","article-title":"Neuartige Krebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester","volume":"45","author":"Arnold","year":"1958","journal-title":"Naturwissen-Schaften"},{"key":"10.1016\/j.urology.2016.07.030_bib0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0305-7372(83)80005-X","article-title":"The development of mesna for regional detoxification","volume":"10","author":"Brock","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urology.2016.07.030_bib0050","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1464-410X.1973.tb12230.x","article-title":"Urological complications of cyclophosphamide","volume":"45","author":"Watson","year":"1973","journal-title":"Br J Urol"},{"key":"10.1016\/j.urology.2016.07.030_bib0055","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3899\/jrheum.150065","article-title":"Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases","volume":"42","author":"Yilmaz","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.urology.2016.07.030_bib0060","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1097-0142(197511)36:5<1572::AID-CNCR2820360506>3.0.CO;2-T","article-title":"Hemorrhagic cystitis in children with leukemia","volume":"36","author":"Lawrence","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2016.07.030_bib0070","first-page":"247","article-title":"Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis","volume":"150","author":"Souza-Fiho","year":"1997","journal-title":"Am J Pathol"},{"issue":"6 Pt 1","key":"10.1016\/j.urology.2016.07.030_bib0075","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1097\/01.ju.0000085593.31396.d8","article-title":"Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats","volume":"170","author":"Korkmaz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2016.07.030_bib0080","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/01.ju.0000154344.80669.e3","article-title":"Peroxinitrite may be involved in bladder damage caused by cyclophosphamide in rats","volume":"173","author":"Korkmaz","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2016.07.030_bib0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10565-006-0078-0","article-title":"Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation","volume":"23","author":"Korkmaz","year":"2007","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.urology.2016.07.030_bib0090","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s11255-014-0833-8","article-title":"Prevention of cyclophosphamide-induced hemorrhagic cystitis by resveratrol: a comparative experimental study with mesna","volume":"46","author":"Keles","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urology.2016.07.030_bib0095","first-page":"199","article-title":"Mechanisms of hemorrhagic cystitis","volume":"2","author":"Haldar","year":"2014","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.urology.2016.07.030_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/luts.12045","article-title":"Advances in therapeutic development for radiation cystitis","volume":"6","author":"Rajaganapathy","year":"2014","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2016.07.030_bib0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2016.07.030_bib0110","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1200\/JCO.1991.9.11.2016","article-title":"Mesna versus hyperhydration for the prevention of cyclophosphamide- induced hemorrhagic cystitis in bone marrow transplantation","volume":"9","author":"Shepherd","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2016.07.030_bib0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000012062","article-title":"Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients","volume":"57","author":"Ballen","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.urology.2016.07.030_bib0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000070964","article-title":"Monitoring hyperhydration during high-dose chemotherapy: body weight or fluid balance?","volume":"109","author":"Mank","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.urology.2016.07.030_bib0125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/pbc.20617","article-title":"Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide","volume":"49","author":"Khaw","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.urology.2016.07.030_bib0130","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-006-0307-5","article-title":"Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis","volume":"59","author":"Lima","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urology.2016.07.030_bib0135","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.juro.2015.07.088","article-title":"Target inhibition of IL-1 receptor prevents ifosfamide induced hemorrhagic cystitis in mice","volume":"194","author":"Leite","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2016.07.030_bib0140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4062\/biomolther.2014.126","article-title":"Diallyl disulfide prevents cyclophosphamide-induced hemorrhagic cystitis in rats through the inhibition of oxidative damage, MAPKs, and NF-\u03baB pathways","volume":"23","author":"Kim","year":"2015","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.urology.2016.07.030_bib0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jbt.21494","article-title":"Uroprotective effect of pentoxifylline in cyclophosphamide-induced hemorrhagic cystitis in rats","volume":"27","author":"Abo-Salem","year":"2013","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.urology.2016.07.030_bib0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ptr.1379","article-title":"Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats","volume":"18","author":"Vieira","year":"2004","journal-title":"Phytother Res"},{"key":"10.1016\/j.urology.2016.07.030_bib0155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10753-011-9319-3","article-title":"Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis","volume":"35","author":"Macedo","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.urology.2016.07.030_bib0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/0253-7613.125188","article-title":"Comparison of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats","volume":"46","author":"Ali","year":"2014","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.urology.2016.07.030_bib0165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/0253-7613.129301","article-title":"Protective effect of ketamine against hemorrhagic cystitis in rats receiving ifosfamide","volume":"46","author":"Ozguven","year":"2014","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.urology.2016.07.030_bib0170","doi-asserted-by":"crossref","first-page":"576","DOI":"10.12968\/hmed.2012.73.10.576","article-title":"Ketamine cystitis: an emerging diagnostic and therapeutic challenge","volume":"73","author":"Gray","year":"2012","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.urology.2016.07.030_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0131882","article-title":"The quinovic acid glycosides purified fraction from Uncaria tomentosa protects against hemorrhagic cystitis induced by cyclophosphamide in mice","volume":"10","author":"Dietrich","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.urology.2016.07.030_bib0180","author":"National Center for Biotechnology Information"},{"key":"10.1016\/j.urology.2016.07.030_bib0185","author":"National Center for Biotechnology Information"},{"key":"10.1016\/j.urology.2016.07.030_bib0190","author":"National Center for Biotechnology Information"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429516304587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429516304587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T20:56:48Z","timestamp":1536440208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429516304587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":36,"alternative-id":["S0090429516304587"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2016.07.030","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2016.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}